{"id":56255,"date":"2024-02-07T05:58:35","date_gmt":"2024-02-07T05:58:35","guid":{"rendered":"https:\/\/medsname.com\/skizoril\/"},"modified":"2026-04-30T10:24:39","modified_gmt":"2026-04-30T10:24:39","slug":"skizoril","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/skizoril\/","title":{"rendered":"Skizoril"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 \u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u0391\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n

Skizoril (Clozapine 25 \/ 50 \/ 100 mg) is the most effective antipsychotic for treatment-resistant schizophrenia, but with the heaviest monitoring burden in modern psychiatry. Mandatory weekly FBC for the first 18 weeks because of agranulocytosis risk. Specialist initiation only.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

Skizoril at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a> \u2014 \u03c0\u03b1\u03c1\u03ac\u03b8\u03c5\u03c1\u03bf \u03ac\u03c6\u03b9\u03be\u03b7\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03ae \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c7\u03c9\u03c1\u03af\u03c2 \u03c7\u03c1\u03ad\u03c9\u03c3\u03b7 \u2014 \u03ba\u03b1\u03b9 \u03b4\u03b9\u03ba\u03b1\u03b9\u03bf\u03cd\u03c4\u03b1\u03b9 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae \u03c3\u03c4\u03bf \u03c0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03b1\u03c6\u03bf\u03c3\u03af\u03c9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>. \u0394\u03b9\u03b1\u03c4\u03af\u03b8\u03b5\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c3\u03c4\u03b9\u03c2 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03c0\u03c1\u03bf\u03bf\u03c1\u03b9\u03c3\u03bc\u03bf\u03cd\u03c2.<\/p>\n

What Skizoril is and how it works<\/h2>\n

Skizoril is a clozapine tablet supplied by Sun Pharma. Available strengths: 25 \/ 50 \/ 100 mg<\/strong>. Clozapine is the most effective antipsychotic ever developed for treatment-resistant schizophrenia (CATIE Phase 2, 2006; CUtLASS 1, 2006). It is also the only antipsychotic with reproducible evidence for reducing suicide rate in schizophrenia (InterSePT, 2003). The mechanism is broad: weak D2 antagonism (low EPS, low TD), strong 5-HT2A and D4 antagonism, strong \u03b11 and H1 blockade, and strong M1\/M3 antagonism. Despite its efficacy, clozapine is reserved for treatment-resistant disease because of the severe monitoring burden.<\/p>\n

\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/h2>\n\n\n\n\n\n\n\n\n
\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\n\u0395\u03ba\u03ba\u03af\u03bd\u03b7\u03c3\u03b7<\/th>\n\u03a3\u03c4\u03cc\u03c7\u03bf\u03c2<\/th>\n\u039c\u03ad\u03b3\u03b9\u03c3\u03c4\u03bf<\/th>\n<\/tr>\n<\/thead>\n
Treatment-resistant schizophrenia<\/td>\n12.5 mg HS day 1, then 25 mg BID, then up by 25\u201350 mg\/day<\/td>\n300\u2013450 mg\/day in divided doses<\/td>\n900 mg<\/td>\n<\/tr>\n
Schizophrenia with suicidality<\/td>\nsame as above<\/td>\nsame<\/td>\nsame<\/td>\n<\/tr>\n
Treatment-resistant bipolar (off-label)<\/td>\n12.5 mg HS<\/td>\n200\u2013500 mg\/day<\/td>\nby tolerability<\/td>\n<\/tr>\n
Older adults<\/td>\n12.5 mg OD<\/td>\n50\u2013200 mg\/day<\/td>\nby tolerability<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Slow titration is mandatory \u2014 fast titration produces severe orthostasis and seizures. The “dose drop” rule: if a patient misses \u2265 2 days of clozapine, restart from low dose and re-titrate.<\/p>\n

\u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b1\u03c3\u03c6\u03b1\u03bb\u03b9\u03c3\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b5\u03ba\u03c4\u03b9\u03bc\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\nMandatory FBC monitoring \u2014 agranulocytosis<\/strong><\/p>\n

Clozapine causes a clinically significant neutropenia in approximately 3% of patients and severe agranulocytosis (ANC < 500) in approximately 0.8%. Risk is highest in the first 18 weeks but never zero. Mandatory FBC schedule:<\/strong> baseline \u2192 weekly \u00d7 18 weeks \u2192 2-weekly \u00d7 weeks 19\u201352 \u2192 monthly thereafter. Stop immediately if ANC drops below cut-offs (varies by registry: usually < 1500 amber, < 1000 red). Most countries require a national clozapine registry that the prescriber and dispensing pharmacy must check before each supply.<\/p>\n<\/div>\n

\nMyocarditis and cardiomyopathy<\/strong><\/p>\n

Clozapine causes myocarditis (especially in the first 4 weeks) and dilated cardiomyopathy (months to years later). Baseline ECG, troponin, CRP, and echocardiogram are increasingly recommended. Stop immediately for unexplained chest pain, dyspnoea, fever, palpitations, or unexplained tachycardia in the first 6\u20138 weeks.<\/p>\n<\/div>\n

\nSeizures (dose-dependent)<\/strong><\/p>\n

~1% at 300 mg\/day; ~5% at 600+ mg\/day. Anticonvulsant cover (often valproate) is added for high-dose clozapine. Avoid drugs that lower seizure threshold (bupropion, tramadol).<\/p>\n<\/div>\n

\nSevere constipation \/ ileus<\/strong><\/p>\n

The strong M1\/M3 anticholinergic effect produces severe constipation and rare cases of ileus, megacolon, and bowel necrosis (clozapine-induced gastrointestinal hypomotility, CIGH). Mortality from CIGH may exceed agranulocytosis mortality. Active bowel-motility management from initiation.<\/p>\n<\/div>\n

\nHeavy metabolic burden<\/strong><\/p>\n

Clozapine produces the heaviest weight gain and metabolic syndrome of any antipsychotic \u2014 alongside olanzapine. Mandatory monitoring of weight, fasting glucose, fasting lipids.<\/p>\n<\/div>\n

\nSialorrhoea<\/strong><\/p>\n

Most patients drool, particularly at night. Counterintuitive (anticholinergic effect should reduce salivation; clozapine paradoxically stimulates salivary M4 receptors). Manageable with topical atropine drops or clonidine.<\/p>\n<\/div>\n

\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n